INO-9012/Human papillomavirus vaccine(University of Pennsylvania) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This INO-9012/Human papillomavirus vaccine(University of Pennsylvania) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether INO-9012/Human papillomavirus vaccine(University of Pennsylvania) can convert its DNA vaccine, Therapeutic vaccine profile and HPV E6 x HPV E7 x IL-12 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | INO-9012/Human papillomavirus vaccine(University of Pennsylvania) (query alias: INO-9012/Human papillomavirus vaccine(University of Pennsylvania)) |
|---|---|
| Modality / target | DNA vaccine, Therapeutic vaccine; HPV E6 x HPV E7 x IL-12; E7 inhibitors, HPV E6 inhibitors, IL-12 modulators |
| Highest global status | Phase 2 |
| Originator | University of Pennsylvania |
| Active developers | University of Pennsylvania |
The MCP disease footprint includes Head and Neck Neoplasms, Uterine Cervical Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07722741 | Phase 2 | Recruiting | 90 | Primary endpoint not disclosed in English source |
| NCT04367675 | Phase 1 | Active, not recruiting | 44 | Primary endpoint not disclosed in English source |
| NCT04251117 | Phase 1/2 | Active, not recruiting | 36 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Phase 1/2; n=35; evaluation: Not stated in English source. Reported fields: Participants with TEAEs = 27 Pts ; Participants with TEAEs = 8 Pts
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Phase 1; n=9; evaluation: Not stated in English source. Reported fields: Safety and Tolerability of a Personalized Neoantigen DNA Vaccine as Measured by Number of Participants With Dose-limiting Toxicities (DLTs) = 0 Pts
Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals withBRCA1/2mutations.
Phase 1; n=42; evaluation: Positive. Reported fields: AE = 95 % ; AE = 95 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
INO-9012/Human papillomavirus vaccine(University of Pennsylvania) addresses Head and Neck Neoplasms, Uterine Cervical Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—DNA vaccine, Therapeutic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 8 matched transaction record(s) under the scope “target-level comparable: HPV E6 x HPV E7 x IL-12.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HPV E6 x HPV E7 x IL-12 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-01-28 | HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics | IND Approval | Financial terms not disclosed |
| 2024-01-04 | INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) | Approved | Financial terms not disclosed |
| 2023-07-27 | SQZ Biotechnologies Provides Update on Collaboration with Roche | Discovery | US$125.0M upfront; US$1,250.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Immunogenicity durability and clinically meaningful protection
- Population selection, endpoint timing, and comparator relevance
- Manufacturing consistency, distribution, and uptake
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
